A novel anti-CD25 ADC using a DNA crosslinking agent of the pyrrolobenzodiazepine dimer (PBD) class [ADCT-301, camidanlumab tesirine (Cami-T)] showed preclinical activity in lymphoma mouse models (37), clinical activity in heavily pretreated Hodgkin lymphoma patients (38) and is currently under investigation in a clinical trial for patients with AML and acute lymphoblastic leukemia (ALL) (NCT02588092). The gene discussed is IL2RA; the disease is acute lymphoblastic leukemia.